Minocyline HCI (rPeptide, Cat#N-3013-2)

Displays antiapoptotic, anti-inflammatory1 activity. Prevents neuropathic pain in a rat sciatic nerve injury model[1]. Reduces MMP-9 activity[2]. Attenuates disease severity in mouse models of multiple sclerosis[3]. Displays neuroprotective activity[4]. May be effective in methotrexate-induced lung fibrosis[5]. Orally active and brain penetrant.